See more : Plat’Home Co., Ltd. (6836.T) Income Statement Analysis – Financial Results
Complete financial analysis of Millendo Therapeutics, Inc. (MLND) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Millendo Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- ASIA Capital Group Public Company Limited (ACAP.BK) Income Statement Analysis – Financial Results
- Bexil Corporation (BXLC) Income Statement Analysis – Financial Results
- Anvia Holdings Corporation (ANVV) Income Statement Analysis – Financial Results
- Nowigence, Inc. (NOWG) Income Statement Analysis – Financial Results
- DCW Limited (DCW.NS) Income Statement Analysis – Financial Results
Millendo Therapeutics, Inc. (MLND)
About Millendo Therapeutics, Inc.
Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 295.00K | 653.00K | 277.00K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 790.00K | 5.40M | 2.25M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | -495.00K | -4.75M | -1.97M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | -167.80% | -727.11% | -711.91% | 0.00% | 0.00% | 0.00% |
| Research & Development | 20.37M | 27.84M | 14.43M | 18.34M | 21.64M | 18.43M | 21.78M | 15.80M | 6.32M |
| General & Administrative | 15.60M | 17.56M | 12.45M | 0.00 | 0.00 | 0.00 | 0.00 | 13.33M | 7.21M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.60M | 17.56M | 12.45M | 0.00 | 0.00 | 0.00 | 0.00 | 13.33M | 7.21M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 27.74M | 49.22M | 51.59M | 26.15M | 0.00 | 0.00 |
| Operating Expenses | 35.97M | 45.40M | 26.87M | 46.08M | 70.86M | 70.03M | 47.93M | 29.13M | 13.53M |
| Cost & Expenses | 35.97M | 45.40M | 26.87M | 46.87M | 76.27M | 72.28M | 47.93M | 29.13M | 13.53M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | -1.04M | 134.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.10M | 1.05M | 32.00K | 1.65M | 2.24M | 1.29M | 450.00K | 231.00K | 93.00K |
| EBITDA | -35.30M | -44.55M | -27.03M | -49.26M | -79.82M | -71.86M | -49.07M | -28.81M | -13.42M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -16,697.63% | -12,223.74% | -25,941.52% | 0.00% | 0.00% | 0.00% |
| Operating Income | -35.97M | -45.40M | -26.87M | -46.58M | -75.61M | -72.00M | -47.93M | -29.13M | -13.53M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -15,788.47% | -11,579.17% | -25,992.42% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -434.00K | 831.00K | -303.00K | -4.33M | -6.45M | -1.15M | -1.59M | 90.00K | 19.00K |
| Income Before Tax | -36.41M | -44.57M | -27.18M | -50.91M | -82.06M | -73.14M | -49.52M | -29.04M | -13.51M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -17,256.95% | -12,566.46% | -26,405.78% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -434.00K | -207.00K | -169.00K | 67.00K | 201.00K | 75.00K | -1.59M | 90.00K | 19.00K |
| Net Income | -36.41M | -44.57M | -27.19M | -50.98M | -82.26M | -73.22M | -49.52M | -29.04M | -13.51M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -17,279.66% | -12,597.24% | -26,432.85% | 0.00% | 0.00% | 0.00% |
| EPS | -28.95 | -48.77 | -263.65 | -321.49 | -575.72 | -608.24 | -491.98 | -404.39 | -523.20 |
| EPS Diluted | -28.95 | -48.77 | -263.65 | -321.49 | -575.72 | -608.24 | -491.98 | -404.39 | -523.20 |
| Weighted Avg Shares Out | 1.26M | 913.79K | 103.14K | 158.56K | 142.88K | 120.38K | 100.65K | 71.82K | 25.82K |
| Weighted Avg Shares Out (Dil) | 1.26M | 913.79K | 103.14K | 158.56K | 142.88K | 120.38K | 100.65K | 71.82K | 25.82K |
Tempest and Millendo Announce Stockholder Approval of Merger
Tempest to Trade on Nasdaq Public Markets Under Ticker “TPST” Tempest to Trade on Nasdaq Public Markets Under Ticker “TPST”
MILLENDO INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Millendo Therapeutics, Inc. - MLND
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Millendo Therapeutics, Inc. (NasdaqGS: MLND) (“the Company”) with Tempest Therapeutics, Inc....
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Millendo Therapeutics, Inc. - MLND
NEW YORK, April 2, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State...
Millendo Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Millendo Therapeutics, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – MLND
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of Millendo Therapeutics, Inc. (NASDAQ: MLND) and Tempest Therapeutics, Inc. is fair to Millendo shareholders. Upon completion of the merger, Millendo shareholders are expected...
MLND Stock Price Falls Over 10% Pre-Market: Why It Happened
The stock price of Millendo Therapeutics Inc (NASDAQ: MLND) fell by over 10% pre-market. This is why it happened.
Tempest Therapeutics To Go Public Via Millendo Therapeutics Merger
Millendo Therapeutics Inc (NASDAQ: MLND) has agreed to merge with privately-held Tempest Therapeutics Inc in an all-stock transaction. The combined company will operate under the Tempest Therapeutics moniker under ticker 'TPST,' focusing on advancing Tempest's oncology pipeline of small molecule candidates.
Tempest and Millendo Announce Proposed Merger Agreement
SOUTH SAN FRANCISCO, Calif. & ANN ARBOR, Mich.--(BUSINESS WIRE)--Tempest Therapeutics, Inc. (“Tempest”), a privately-held clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, and Millendo Therapeutics, Inc. (Nasdaq: MLND) (“Millendo”), announced today that they have...
Millendo Therapeutics Reports Second Quarter 2020 Operating and Financial Results
Millendo Therapeutics Reports Second Quarter 2020 Operating and Financial Results
Millendo Therapeutics (NASDAQ:MLND) Cut to “Hold” at Zacks Investment Research
Millendo Therapeutics (NASDAQ:MLND) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Tuesday, Zacks.com reports. According to Zacks, “Millendo Therapeutics Inc. is a biopharmaceutical company. It focuses on developing...
Zacks Investment Research Upgrades Millendo Therapeutics (NASDAQ:MLND) to Buy
Zacks Investment Research upgraded shares of Millendo Therapeutics (NASDAQ:MLND) from a hold rating to a buy rating in a report published on Thursday morning, Zacks.com reports. Zacks Investment Research currently has $1.75 target price on the stock. According to Zacks,...
Source: https://incomestatements.info
Category: Stock Reports